WB, IP, IF-F, IF-IC, FC-FP, ChIP
H M R
Endogenous
60-80
Rabbit IgG
#Q96NM4, #O94900
84969, 9760
Product Information
Product Usage Information
For optimal ChIP results, use 10 μl of antibody and 10 μg of chromatin (approximately 4 × 106 cells) per IP. This antibody has been validated using SimpleChIP® Enzymatic Chromatin IP Kits.
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Immunoprecipitation | 1:100 |
| Immunofluorescence (Frozen) | 1:100 - 1:400 |
| Immunofluorescence (Immunocytochemistry) | 1:100 - 1:400 |
| Flow Cytometry (Fixed/Permeabilized) | 1:200 - 1:800 |
| Chromatin IP | 1:50 |
Storage
For a carrier free (BSA and azide free) version of this product see product #86380.
Specificity / Sensitivity
Species Reactivity:
Human, Mouse, Rat
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Gln435 of human Tox protein.
Background
Thymocyte selection-associated high mobility group box protein (Tox) is a DNA-binding nuclear factor and member of the evolutionarily conserved high-motility group (HMG)-box superfamily. Tox also defines a small subfamily of proteins that include Tox2, Tox3, and Tox4, all of which are highly conserved in vertebrate species but have unique tissue expression patterns and functions (1,2).
Tox plays a key role in T cell development in the thymus during positive selection (3-5). A study in Tox-deficient mice also revealed a requirement for Tox in CD4 T cell and NK cell lineage development, including NKT cells, FoxP3+ T regulatory T cells, and lymphoid tissue-inducer (LTi) cells (6-8). Although Tox expression is primarily restricted to developing immune cells in normal tissues, Tox is induced by high antigen stimulation during chronic viral infection or cancer, regulating T cell persistence and exhaustion (9-12). Tox has also been shown to be aberrantly expressed in cutaneous T cell lymphomas (13-14).
- O'Flaherty, E. and Kaye, J. (2003) BMC Genomics 4, 13.
- Aliahmad, P. et al. (2012) Curr Opin Immunol 24, 173-7.
- Wilkinson, B. et al. (2002) Nat Immunol 3, 272-80.
- Aliahmad, P. et al. (2004) J Exp Med 199, 1089-99.
- Chi, T.H. et al. (2002) Nature 418, 195-9.
- Aliahmad, P. and Kaye, J. (2008) J Exp Med 205, 245-56.
- Aliahmad, P. et al. (2010) Nat Immunol 11, 945-52.
- Yun, S. et al. (2011) Immunol Lett 136, 29-36.
- Page, N. et al. (2018) Immunity 48, 937-950.e8.
- Alfei, F. et al. (2019) Nature 571, 265-9.
- Yao, C. et al. (2019) Nat Immunol 20, 890-901.
- Wang, X. et al. (2019) J Hepatol pii: S0168-8278(19)30301-0. doi: 10.1016/j.jhep.2019.05.015.
- Morimura, S. et al. (2014) Arch Dermatol Res 306, 843-9.
- Huang, Y. et al. (2014) Oncotarget 5, 4418-25.
Species Reactivity
Species reactivity is determined by testing in at least one approved application (e.g., western blot).
Western Blot Buffer
IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.
Applications Key
WB: Western Blotting IP: Immunoprecipitation IF-F: Immunofluorescence (Frozen) IF-IC: Immunofluorescence (Immunocytochemistry) FC-FP: Flow Cytometry (Fixed/Permeabilized) ChIP: Chromatin IP
Cross-Reactivity Key
H: human M: mouse R: rat Hm: hamster Mk: monkey Vir: virus Mi: mink C: chicken Dm: D. melanogaster X: Xenopus Z: zebrafish B: bovine Dg: dog Pg: pig Sc: S. cerevisiae Ce: C. elegans Hr: horse GP: Guinea Pig Rab: rabbit All: all species expected
Trademarks and Patents
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.
